Akademibokhandeln
Paloma H. Giangrande, Vittorio de Franciscis, John J. Rossi - RNA Therapeutics, Häftad

Häftad, Engelska, 2022

RNA Therapeutics

The Evolving Landscape of RNA Therapeutics

Av Paloma H. Giangrande, Vittorio de Franciscis, John J. Rossi

2409 kr

Beställningsvara. Skickas inom 11-20 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Finns i fler format

Beskrivning

RNA Therapeutics: The Evolving Landscape of RNA Therapeutics provides a comprehensive overview of RNA therapeutic modalities, from bench-to-bedside, with an emphasis on the increasingly impactful areas of gene therapy, oligonucleotide therapeutics, gene editing and delivery. International leaders in the field examine RNA-based therapeutics tools that have been developed to-date to modulate cellular processes such as transcription, translation and protein function. Approved RNA-based therapies and lessons learned from failed therapies are discussed in-depth, as are evolving advances in RNA biochemical analysis, and similar advances that are enabling clinical application of RNA-based therapies.

Later sections discuss delivery technologies, remaining hurdles in research and translation, the therapy development process from the lab to the clinic, and novel RNA-based therapies currently in development.



  • Features leading experts in the field of RNA therapeutics, spanning all classes of RNA therapies
  • Provides a detailed examination of approved RNA therapies and lessons learned from failed therapeutics
  • Covers all aspects of therapeutic discovery and preclinical development, as well as clinical translation, manufacturing and regulatory aspects
Produktinformation
  • Utgivningsdatum: 2022-04-13
  • Mått: 191 x 235 x 32 mm
  • Vikt: 970 g
  • Format: Häftad
  • Språk: Engelska
  • Antal sidor: 472
  • Förlag: Elsevier Science
  • ISBN: 9780128215951
Utforska kategorier
Mer information

Dr. Paloma Giangrande is the VP of Biology at Wave Life Sciences, Cambridge, MA and Adjunct Associate Professor of Internal Medicine at the University of Iowa, Iowa City, IA. Her career has been dedicated to the investigation and development of RNA-based therapeutic approaches (including RNA aptamers, siRNAs, and mRNA) for cancer, cardiovascular disease, rare diseases, and critical illness. As a consequence, she has developed a deep understanding of these technologies, diseases, and associated disease mechanisms. She is also an internationally recognized expert in oligonucleotide therapeutics and delivery. Towards this end, she was the first to demonstrate that RNA ligands (aptamers) can be used to deliver therapeutic siRNAs to target cells. Her 60+ publications and 9+ patents are a testament to this body of work and her commitment to the development of novel RNA-based therapies for many diseases. Dr. Vittorio de Franciscis is Senior Collaborator at the CNR Institute of Genetic and Biomedical Research (IRGB) in Milan Italy. For more than ten years, the interest of the research has focused on translating the understanding of the molecular basis of neoplastic transformation in the design of selective therapies based on the use of therapeutic RNAs (aptamers, siRNAs, miRNAs). In his laboratory, they demonstrated the possibility of generating aptamers that bind to high affinity and inhibit transmembrane receptors involved in cancer progression (including, EGFR, AXL, PDGFR, IR, Eph). For the selection of aptamers they have developed a variant of the SELEX technology that makes use of living cells as a complex target. They have recently shown that such RNA aptamers against RTK can be used as targeting moieties for the selective delivery of therapeutic miRNAs and anti-miRs, against tumor cells and tissues.

Recensioner i media

Select Guide Rating

Butikslager

Ej i lager i butik.

Betyg & recensioner

0 recensioner

Inga recensioner tillgängliga.